US · NVS
Novartis AG
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Basel 4056
- Website
- novartis.com
Price · as of 2025-12-31
$146.57
Market cap 325.95B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $120.04 | -18.1% |
| Intrinsic Value(DCF) | $84.22 | -42.54% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $100.54 | -31.4% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $30.41 | $49.46 | $19.13 | $0.03 | $85.08 |
| 2012 | $39.83 | $48.07 | $10.14 | $0.00 | $0.00 |
| 2013 | $49.84 | $55.85 | $10.60 | $0.00 | $35.59 |
| 2014 | $59.82 | $65.83 | $9.15 | $0.00 | $41.46 |
| 2015 | $47.68 | $45.24 | $5.64 | $14.62 | $17.70 |
| 2016 | $50.18 | $46.35 | $7.10 | $0.00 | $18.09 |
| 2017 | $54.94 | $49.55 | $8.11 | $0.00 | $0.00 |
| 2018 | $61.71 | $62.95 | $13.74 | $0.81 | $76.45 |
| 2019 | $67.96 | $58.98 | $6.59 | $0.00 | $69.07 |
| 2020 | $71.89 | $60.41 | $12.48 | $0.00 | $37.64 |
| 2021 | $70.39 | $81.83 | $18.07 | $21.25 | $0.00 |
| 2022 | $71.82 | $58.00 | $11.37 | $0.00 | $22.27 |
| 2023 | $93.56 | $73.32 | $12.37 | $0.00 | $108.75 |
| 2024 | $111.42 | $91.40 | $32.82 | $0.00 | $109.22 |
| 2025 | $166.87 | $120.04 | $54.85 | $0.00 | $100.54 |
AI valuation
Our deep-learning model estimates Novartis AG's (NVS) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $120.04
- Current price
- $146.57
- AI upside
- -18.1%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$84.22
-42.54% upside
Graham-Dodd
—
— upside
Graham Formula
$100.54
-31.4% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NVS | Novartis AG | $146.57 | 325.95B | -18% | -43% | — | -31% | 23.02 | 7.01 | 5.90 | 15.18 | 102.37 | -36.57 | 75.02% | 31.15% | 25.64% | 31.17% | 21.84% | 12.91% | 0.80 | 14.38 | 1.12 | 0.83 | 1.11 | 2249.00% | 597.00% | 2811.00% | 5.47% | 0.71 | 26.49% | 2.43% | 55.90% | 5.29% | 20.44 | 19.73 | 6.37 | 4.35 |
| ABBV | AbbVie Inc. | $232.03 | 410.27B | -31% | -54% | — | -83% | 99.26 | -128.28 | 6.86 | 17.08 | — | -4.58 | 83.71% | 34.69% | 6.91% | 15367.27% | 21.58% | 3.14% | -21.12 | 8.08 | 0.67 | 0.41 | 2.26 | -126.00% | 857.00% | -9.00% | 4.25% | 0.44 | 28.25% | 2.78% | 275.80% | 3.01% | 22.78 | 27.13 | 7.90 | 2.52 |
| AZN | AstraZeneca PLC | $208.45 | 646.31B | -44% | -57% | -100% | -74% | 61.77 | 12.98 | 10.75 | 33.06 | 32.62 | -60.60 | 81.90% | 23.40% | 17.46% | 22.86% | 16.43% | 9.38% | 0.61 | 8.11 | 0.94 | 0.68 | 1.21 | 18938.00% | 863.00% | 6172.00% | 1.86% | 0.48 | 17.05% | 0.80% | 49.70% | 1.02% | 47.70 | 55.72 | 11.16 | 6.83 |
| BMY | Bristol-Myers Squibb Comp… | $62.37 | 127.01B | +7% | -50% | — | -56% | 18.03 | 6.89 | 2.64 | 11.25 | — | -5.68 | 67.65% | 26.34% | 14.63% | 40.54% | 17.21% | 7.73% | 2.55 | 8.41 | 1.26 | 1.08 | 2.54 | -17823.00% | -22.00% | -787.00% | 10.10% | 0.60 | 23.02% | 3.97% | 71.50% | 7.05% | 12.89 | 12.74 | 3.40 | 2.41 |
| GILD | Gilead Sciences, Inc. | $148.95 | 184.8B | -18% | -32% | — | -52% | 21.93 | 8.25 | 6.34 | 18.54 | 1.30 | -69.80 | 86.69% | 40.14% | 28.90% | 40.57% | 28.89% | 14.42% | 1.09 | 11.54 | 1.68 | 1.31 | 1.57 | 168421.00% | 240.00% | -824.00% | 5.07% | 0.85 | 26.61% | 2.14% | 47.00% | 3.17% | 16.98 | 21.22 | 6.81 | 4.40 |
| GSK | GSK plc | $59.13 | 119.27B | 0% | -48% | — | -38% | 15.76 | 5.39 | 2.76 | 8.81 | 13.21 | -11.95 | 72.54% | 21.95% | 17.50% | 37.25% | 20.70% | 9.28% | 1.08 | 10.23 | 0.82 | 0.52 | 1.23 | 11935.00% | 183.00% | 6306.00% | 6.61% | 0.33 | 20.23% | 2.85% | 44.90% | 2.85% | 14.61 | 17.58 | 3.21 | 2.24 |
| JNJ | Johnson & Johnson | $248.43 | 598.69B | -22% | -48% | — | -38% | 22.52 | 7.40 | 6.41 | 15.83 | 24.88 | -34.24 | 72.78% | 27.17% | 28.46% | 35.03% | 21.82% | 14.13% | 0.59 | 26.36 | 1.03 | 0.69 | 0.71 | 9050.00% | 605.00% | -73.00% | 3.26% | 0.45 | 20.41% | 2.05% | 46.20% | 3.04% | 24.67 | 32.06 | 6.70 | 5.17 |
| LLY | Eli Lilly and Company | $1,052.20 | 992.6B | -41% | +26% | -95% | +11% | 44.29 | 34.45 | 14.03 | 33.98 | 46.14 | 64.76 | 83.79% | 45.56% | 31.66% | 101.36% | 44.87% | 21.59% | 1.60 | 37.34 | 1.58 | 0.78 | 1.27 | 9599.00% | 4470.00% | 206558.00% | 0.98% | 0.48 | 16.90% | 0.59% | 26.10% | 1.04% | 31.97 | 105.82 | 14.57 | 8.36 |
| MRK | Merck & Co., Inc. | $123.78 | 306.03B | +5% | -27% | -61% | -44% | 16.68 | 5.79 | 4.68 | 13.42 | 208.16 | 70.05 | 81.50% | 41.19% | 28.08% | 36.91% | 29.12% | 17.40% | 0.96 | — | 1.54 | 0.96 | 1.42 | 801.00% | 131.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | 12.71 | — | 5.24 | 5.12 |
| PFE | Pfizer Inc. | $27.65 | 157.21B | +59% | -45% | -66% | -67% | 19.93 | 1.79 | 2.48 | 13.65 | — | -4.02 | 70.33% | 24.67% | 12.42% | 8.90% | 11.33% | 3.69% | 0.75 | 5.78 | 1.16 | 0.37 | 4.22 | -355.00% | -165.00% | -773.00% | 5.86% | 0.32 | 6.66% | 0.00% | 0.00% | 1.48% | 13.35 | 22.71 | 3.29 | 2.12 |
| SNY | Sanofi | $48.66 | 117.52B | -6% | +222% | -59% | +2% | 12.72 | 1.39 | 2.13 | 8.95 | — | 26.05 | 72.34% | 13.58% | 16.72% | 10.50% | 6.06% | 6.02% | 0.31 | 11.73 | 1.09 | 0.28 | 1.11 | -731.00% | 549.00% | 5107.00% | 8.95% | 0.38 | 10.28% | 4.61% | 58.70% | 9.47% | 17.90 | 12.77 | 2.43 | 1.64 |
About Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
- CEO
- Vasant Narasimhan
- Employees
- 75.88K
- Beta
- 0.46
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($84.22 ÷ $146.57) − 1 = -42.54% (DCF, example).